Outcome of antimicrobial therapy of pediatric urinary tract infections caused by extended-spectrum β-lactamase-producing enterobacteriaceae

Infection and Chemotherapy

Volumn 45, Issue 4, 2013, Pages 415-421

  Lee, Bongjin ^a   Kang, Soo Young ^a   Kang, Hyun Mi ^a   Yang, Nu Ri ^a   Kang, Hee Gyung ^a,b   Ha, Il Soo ^a,b   Cheong, Hae Il ^a,b   Lee, Hoan Jong ^a,b   Choi, Eun Hwa ^a,b  

^a Seoul National University Children's Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Carbapenem; Children; Enterobacteriaceae; Extended spectrum lactamase; Urinary tract infections

Indexed keywords

CARBAPENEM;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CHILD; CLINICAL ARTICLE; CONGENITAL MALFORMATION; CONTROLLED STUDY; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; HUMAN; HYDRONEPHROSIS; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MALE; MEDICAL RECORD REVIEW; NEUROGENIC BLADDER; PRESCHOOL CHILD; RECURRENCE RISK; RETROSPECTIVE STUDY; TREATMENT OUTCOME; URINARY TRACT INFECTION; VESICOURETERAL REFLUX;

EID: 84893172370     PISSN: 20932340     EISSN: 20926448     Source Type: Journal    
DOI: 10.3947/ic.2013.45.4.415     Document Type: Article

References (28)

1. Zorc JJ, Kiddoo DA, Shaw KN. Diagnosis and management of pediatric urinary tract infections. Clin Microbiol Rev 2005;18:417-22.
2. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983;11:315-7.
3. Bauernfeind A, Hörl G. Novel R-factor borne beta-lactamase of Escherichia coli confering resistance to cephalosporins. Infection 1987;15:257-9.
4. Lee J, Pai H, Kim YK, Kim NH, Eun BW, Kang HJ, Park KH, Choi EH, Shin HY, Kim EC, Lee HJ, Ahn HS. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy. J Antimicrob Chemother 2007;60:629-37.
5. Briongos-Figuero LS, Gómez-Traveso T, Bachiller-Luque P, Domínguez-Gil González M, Gómez-Nieto A, Palacios-Martín T, González-Sagrado M, Dueñas-Laita A, Pérez-Castrillón JL. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria. Int J Clin Pract 2012;66:891-6.
6. Yamasaki K, Komatsu M, Abe N, Fukuda S, Miyamoto Y, Higuchi T, Ono T, Nishio H, Sueyoshi N, Kida K, Satoh K, Toyokawa M, Nishi I, Sakamoto M, Akagi M, Nakai I, Kofuku T, Orita T, Wada Y, Jikimoto T, Kinoshita S, Miyamoto K, Hirai I, Yamamoto Y. Laboratory surveillance for prospective plasmid-mediated AmpC beta-lactamases in the Kinki region of Japan. J Clin Microbiol 2010;48:3267-73.
7. Titelman E, Iversen A, Kalin M, Giske CG. Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Microb Drug Resist 2012;18:189-92.
8. Neuner EA, Sekeres J, Hall GS, van Duin D. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemother 2012;56:5744-8.
9. Doi A, Shimada T, Harada S, Iwata K, Kamiya T. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Int J Infect Dis 2012;17:e159-63.
10. Tinelli M, Cataldo MA, Mantengoli E, Cadeddu C, Cunietti E, Luzzaro F, Rossolini GM, Tacconelli E. Epidemiology and genetic characteristics of extended-spectrum betalactamase-producing Gram-negative bacteria causing urinary tract infections in long-term care facilities. J Antimicrob Chemother 2012;67:2982-7.
11. Kizilca O, Siraneci R, Yilmaz A, Hatipoglu N, Ozturk E, Kiyak A, Ozkok D. Risk factors for community-acquired urinary tract infection caused by ESBL-producing bacteria in children. Pediatr Int 2012;54:858-62.
12. Azap OK, Arslan H, Serefhanoglu K, Colakoglu S, Erdogan H, Timurkaynak F, Senger SS. Risk factors for extendedspectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect 2010;16:147-51.
13. Topaloglu R, Er I, Dogan BG, Bilginer Y, Ozaltin F, Besbas N, Ozen S, Bakkaloglu A, Gur D. Risk factors in community-acquired urinary tract infections caused by ESBL-producing bacteria in children. Pediatr Nephrol 2010;25:919-25.
14. Kim NH, Lee JA, Kim YK, Choi EH, Ha IS, Lee HJ, Choi Y. Risk factors of urinary tract infections due to extendedspectrum beta-lactamase producing Escherichia coli in children. Korean J Pediatr 2004;47:164-9.
15. Lee CH, Su LH, Tang YF, Liu JW. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates. J Antimicrob Chemother 2006;58:1074-7.
16. Apisarnthanarak A, Hsu LY, Khawcharoenporn T, Mundy LM. Carbapenem-resistant Gram-negative bacteria: how to prioritize infection prevention and control interventions in resource-limited settings? Expert Rev Anti Infect Ther 2013;11:147-57.
17. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 19th Informational Supplement. CLSI document M100-S19. Wayne, PA: Clinical and Laboratory Standards Institute;2009.
18. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988;10:867-78.
19. Thomson KS, Sanders CC. Detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae: comparison of the double-disk and threedimensional tests. Antimicrob Agents Chemother 1992;36:1877-82.
20. Dalgic N, Sancar M, Bayraktar B, Dincer E, Pelit S. Ertapenem for the treatment of urinary tract infections caused by extended-spectrum beta-lactamase-producing bacteria in children. Scand J Infect Dis 2011;43:339-43.
21. Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011;17:1791-8.
22. Héritier C, Poirel L, Lambert T, Nordmann P. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 2005;49:3198-202.
23. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006;12:826-36.
24. Pai H, Kim J, Kim J, Lee JH, Choe KW, Gotoh N. Carbapenem resistance mechanisms in Pseudomonas aeruginosa cl inical isolates. Ant imicrob Agents Chemother 2001;45:480-4.
25. Shilo S, Assous MV, Lachish T, Kopuit P, Bdolah-Abram T, Yinnon AM, Wiener-Well Y. Risk factors for bacteriuria with carbapenem-resistant Klebsiella pneumoniae and its impact on mortality: a case-control study. Infection 2013;41:503-9.
26. Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005;352:380-91.
27. Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum eeta-lactamase- producing enterobacteriaceae: MIC matters. Clin Infect Dis 2013;56:488-95.
28. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum ß-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 2012;67:2793-803.